SCHEMBL4431335

SCHEMBL4431335

O=c1n(C2CCNCC2)c2ccccc2n1S(=O)(=O)c1cccc2nsnc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.57
ALDH1A1 P00352 5/20 0.49
CYP1A2 P05177 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2C19 P33261 3/20 0.49
LMNA P02545 2/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 2/20 0.47
MAPK1 P28482 3/20 0.47
USP2 O75604 4/20 0.47
GAA P10253 4/20 0.44
PKM P14618 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4427743 0.75 HTR6 (0.56) KMT2AALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6017214 0.74 KMT2A (0.56) KMT2AALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL4425141 0.74 PKM (0.42) KMT2ACYP2C9CYP2C19MEN1POLB
SCHEMBL13006378 0.72 HTR6 (0.40)
SCHEMBL4424954 0.71 HTR6 (0.42) ALDH1A1CYP2C9CYP2C19LMNAPOLB
SCHEMBL4432222 0.71 HTR6 (0.45) ALDH1A1CYP1A2CYP2C9CYP2C19LMNA
SCHEMBL4418150 0.70 HTR6 (0.56) ALDH1A1LMNAUSP2GAAPKM
SCHEMBL4416818 0.69 HTR6 (0.39) CYP2C9CYP2C19POLBUSP2CYP3A4
SCHEMBL4432215 0.69 MAPT (0.41) ALDH1A1CYP2C9CYP2C19LMNAPOLB
SCHEMBL4420468 0.69 PRKCG (0.41) KMT2AALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US claimed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US claimed
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US disclosed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1B KMT2A 2667/4885ALDH1A1 935/4885CYP1A2 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.